Skip to main content

Table 4 Association between variant detection at different time points and patient’s clinicopathological characteristics

From: Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial

Variable

Patients

CYP2B6 (T1–T2)

CYP2B6 (FU)

BAX (T1–T2)

BAX (FU)

HNF1A (T1–T2)

HNF1A (FU)

n

8

8

4

6

5

12

Portal vein invasion

 Yes

3

3

1

3

1

1

3

 No

10

5

7

1

5

4

9

 p

 

0.231

0.51

0.014*

1

1

1

BCLC

 A + B

7

4

7

1

2

2

7

 C

6

4

1

3

4

3

5

 p

 

1

0.005*

0.266

0.286

0.592

1

Metastases

 Yes

4

3

1

2

3

2

3

 No

9

5

7

2

3

3

9

 p

 

0.608

0.217

0.53

0.266

1

0.538

Cirrhosis

 Yes

8

6

6

3

4

1

7

 No

5

2

2

1

2

4

5

 p

 

0.293

0.293

0.608

1

0.032*

1

Tumor size (cm)

 < 5

6

2

4

2

2

2

6

 > 5

6

5

3

2

3

2

6

 p

 

0.242

1

1

1

1

1

  1. The analysis shows that there is a significant association between variants in CYP2B6, BAX and HNF1A and BCLS status (p = 0.005) portal vein invasion (p = 0.014) and absence of liver cirrhosis (p = 0.032), respectively. No association was found between any variant and presence of metastases or tumor size (all p > 1.0). Comparison was performed (for each time group separately) using the Fischer exact test
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us